SCHEMBL9951173

SCHEMBL9951173

COC(=O)c1ccc(C(CC(C)C)Oc2ccc(-c3ccc(C(F)(F)F)cc3)cc2)nc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.46
GCGR P47871 3/20 0.44
PSEN1 P49768 1/20 0.39
PSEN2 P49810 1/20 0.39
APH1B Q8WW43 1/20 0.39
NCSTN Q92542 1/20 0.39
APH1A Q96BI3 1/20 0.39
PSENEN Q9NZ42 1/20 0.39
GRM4 Q14833 1/20 0.39
PPARD Q03181 1/20 0.38
PPARA Q07869 1/20 0.38
ROCK1 Q13464 1/20 0.38
MYLK4 Q86YV6 1/20 0.38
MAPT P10636 1/20 0.37
SLC6A9 P48067 1/20 0.37
RORC P51449 1/20 0.37
MAPK1 P28482 1/20 0.37
GABRA5 P31644 1/20 0.37
MAOB P27338 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9951071 0.90 GCGR (0.45) GCGRPSEN1PSEN2APH1BNCSTN
SCHEMBL9951288 0.84 GCGR (0.62) GCGR
SCHEMBL9950714 0.82 GCG (0.49) LMNAGCGRPSEN1PSEN2APH1B
SCHEMBL9951065 0.82 LMNA (0.48) LMNAGCGRPSEN1PSEN2APH1B
SCHEMBL9950990 0.76 GCGR (0.61) LMNAGCGRPSEN1PSEN2APH1B
SCHEMBL9950901 0.75 GCG (0.44) LMNAGCGRPSEN1PSEN2APH1B
SCHEMBL2268276 0.75 GCGR (0.50) LMNAGCGRSLC6A9MAPK1
SCHEMBL1765370 0.75 GCGR (0.50) LMNAGCGRSLC6A9MAPK1
SCHEMBL9952589 0.75 MAP4K4 (0.46) GRM4PPARDPPARA
SCHEMBL2273268 0.75 GCGR (0.50) LMNAGCGRSLC6A9MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150266861-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2015-09-24 US disclosed
US-20150266861-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2015-09-24 US disclosed
US-20150266861-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2015-09-24 US disclosed
US-9056834-B2 Glucagon receptor modulators PFIZER INC. (US) 2015-06-16 US disclosed
US-9056834-B2 Glucagon receptor modulators PFIZER INC. (US) 2015-06-16 US disclosed
US-9056834-B2 Glucagon receptor modulators PFIZER INC. (US) 2015-06-16 US disclosed
US-20150094338-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2015-04-02 US disclosed
US-20150094338-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2015-04-02 US disclosed
US-20150094338-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2015-04-02 US disclosed
US-8933104-B2 Glucagon receptor modulators PFIZER INC. (US) 2015-01-13 US disclosed
US-20140329862-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2014-11-06 US disclosed
US-8809342-B2 Glucagon receptor modulators PFIZER INC. (US) 2014-08-19 US disclosed
US-8809342-B2 Glucagon receptor modulators PFIZER INC. (US) 2014-08-19 US disclosed
US-8809342-B2 Glucagon receptor modulators PFIZER INC. (US) 2014-08-19 US disclosed
EP-2655331-A1 GLUCAGON RECEPTOR MODULATORS Pfizer Inc (US) 2013-10-30 EP disclosed
WO-2012085745-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2012-06-28 WO disclosed
US-20120165343-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2012-06-28 US disclosed
WO-2012085745-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2012-06-28 WO disclosed
US-20120165343-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2012-06-28 US disclosed
US-20120165343-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329862-A1 Glucagon Receptor Modulators GLP1R, GCGR, GPR119 LMNA 2805/4885GCGR 2/4885PSEN1 3218/4885
US-20150094338-A1 Glucagon Receptor Modulators GLP1R, GCGR, GPR119 LMNA 2805/4885GCGR 2/4885PSEN1 3218/4885
US-20120165343-A1 Glucagon Receptor Modulators GLP1R, GCGR, GPR119 LMNA 2805/4885GCGR 2/4885PSEN1 3218/4885
US-20150266861-A1 Glucagon Receptor Modulators GLP1R, GCGR, GPR119 LMNA 2805/4885GCGR 2/4885PSEN1 3218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.